Clover Biopharmaceuticals, Ltd. has announced the enrollment of the first group of participants for its Phase I clinical trial evaluating the SCB-1019 vaccine against Respiratory Syncytial Virus (RSV).

The primary reporter is the first person who provides individual safety information, regardless of whether the reporter is a medical professional.

The FDA is reviewing the updated New Drug Application (NDA) for TransCon PTH (also known as Palopegteriparatide) meant for the treatment of hypoparathyroidism in adults.

Protease inhibitors are drugs that inhibit proteases, enzymes crucial in various biological processes.

Vertex Pharmaceuticals Incorporated declared favorable outcomes from its Phase 2 trial assessing various dosages of the targeted NaV1.8 inhibitor, VX-548, in individuals suffering from painful diabetic peripheral neuropathy.

If the applicant / marketing authorisation holder has submitted an RMP for the product, the RMP submitted later should adopt an updated format.

Wugen Unveils Initial Results from Early-Stage Clinical Assessment of WU-CART-007 in Hard-to-Combat Hematologic Malignancies at the Yearly American Hematology Conference.

RIPK1 inhibitors are drugs that target the enzyme RIPK1, crucial in cell death and inflammation regulation.

Connect Biopharma has revealed encouraging primary outcomes from its global Phase 2b trial of Rademikibart in treating adults with moderate to severe chronic asthma.

post marketing research of drugs refers to the research on the use and effect of drugs following a specific research scheme after they are approved for marketing.

GigaGen Inc. has announced FDA approval for its IND application. This permits the start of a Phase 1 trial to evaluate GIGA-564's effectiveness in treating diverse solid cancers.

Protein kinase inhibitors are drugs that target protein kinases, crucial in cell signaling and regulation. The future sees potential applications in treating various diseases, particularly cancer.